- Home
- IDT vs BRVE Comparison
IDT vs BRVE Comparison
Compare IDT & BRVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IDT | BRVE |
|---|---|---|
| Founded | 1990 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.8B |
| IPO Year | 1996 | 2026 |
Fundamental Metrics
Financial Performance| Metric | IDT | BRVE |
|---|---|---|
| Price | $82.88 | $20.70 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $45.25 |
| AVG Volume (30 Days) | 160.2K | ★ 362.3K |
| Earning Date | 12-03-2026 | 11-10-2026 |
| Dividend Yield | ★ 0.34% | N/A |
| EPS Growth | ★ 14.95 | N/A |
| EPS | ★ 3.46 | N/A |
| Revenue | ★ $1,231,495,000.00 | N/A |
| Revenue This Year | $2.39 | N/A |
| Revenue Next Year | $0.75 | N/A |
| P/E Ratio | $24.07 | ★ N/A |
| Revenue Growth | ★ 2.13 | N/A |
| 52 Week Low | $46.48 | $16.70 |
| 52 Week High | $84.56 | $32.00 |
Technical Indicators
Market Signals| Indicator | IDT | BRVE |
|---|---|---|
| Relative Strength Index (RSI) | 58.78 | 48.40 |
| Support Level | $80.22 | $17.93 |
| Resistance Level | $84.56 | $22.22 |
| Average True Range (ATR) | 2.02 | 1.53 |
| MACD | -0.31 | 0.04 |
| Stochastic Oscillator | 68.11 | 67.66 |
Price Performance
Historical ComparisonAbout IDT IDT Corporation Class B
IDT Corp is a multinational holding company. It operates in the telecommunications and payment industries. It has four reportable business segments, Fintech, National Retail Solutions; net2phone and Traditional Communications, The Fintech segment is comprised of National Retail Solutions (NRS), an operator of a nationwide point of sale (POS) network providing payment processing, digital advertising, transaction data, and ancillary services, and BOSS Money, a provider of international money remittance and related value/payment transfer services. The net2phone segment provides unified cloud communications and telephony services to business customers.
About BRVE Braveheart Bio Inc. Common Stock
Braveheart Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics to treat hypertrophic cardiomyopathy (HCM) and other cardiovascular diseases. Its flagship product candidate, BHB-1893, is an oral small-molecule cardiac myosin inhibitor being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM).